Acquistion of an inFlux GMP cell sorter.

描述(由申请人提供)：临床前和临床使用的适合纯化原代人类细胞的荧光激活细胞分选机的需求日益增长。这带来了超出常规研究细胞分选所遇到的技术挑战。主要关注的是降低样本污染的风险，同时保护操作员免受潜在的生物危险气雾剂的影响。目前，华盛顿大学或附近的圣路易斯大学健康科学中心校园内还没有适合对原代人类细胞进行分选的仪器。该提案要求提供资金购买流入细胞分类器(Cytopeia，Inc.)。这种仪器有几个设计特点，使其能够很好地适应人类细胞的分选。流入的细胞将被纳入由PI在华盛顿大学阿尔文·J·西特曼癌症中心(NCI指定的癌症中心)内指导的成功的细胞分选核心设施中。几个主要用户提出的利用流入生产临床级细胞产品的建议将受益于与细胞分选核心相连的最先进的“良好制造实践”(GMP)设施。建造650平方米的建筑。英国《金融时报》用于涌入的空间和支持系统已经完成。持续的运营和服务费用将由西特曼癌症中心提供，并由使用费抵消。一个由西特曼癌症中心高级领导层组成的咨询委员会将监督对涌入的人口的管理和利用。主要用户都是拥有重要细胞学专业知识的知名和资助科学家，在第一年将占100%的利用率，在随后的几年至少占75%。剩下的时间将分配给华盛顿大学和圣路易斯大学的其他调查人员，优先考虑Siteman癌症中心的成员。这一工具将为华盛顿大学的许多资助项目提供附加值，这些项目在2002年总共获得了超过3.28亿美元的NIH奖励，使其在美国医学中心中排名第三。

DESCRIPTION (provided by applicant): There is a growing need for fluorescence-activated cell sorters suitable for purifying primary human cells for preclinical and clinical uses. This poses technical challenges above and beyond those encountered in routine research cell sorting. The primary concerns are reducing the risk of sample contamination while protecting operators from potentially biohazardous aerosols. There are currently no instruments suitable for sorting primary human cells at Washington University or the nearby campus of St. Louis University Health Sciences Center. This proposal requests funds to purchase the inFlux cell sorter (Cytopeia, Inc.). This instrument has several design features that make it well-adapted to sorting human cells. The inFlux will be incorporated into a successful cell sorting core facility directed by the PI within the Alvin J. Siteman Cancer Center at Washington University, an NCI-designated Cancer Center. The proposal by several of the Major Users to use the inFlux for generation of clinical grade cellular products will benefit from a state-of-the-art "Good Manufacturing Practices" (GMP) facility that is contiguous with the cell sorting core. Construction of the 650 sq. ft. space and support systems for the inFlux have been completed. Ongoing costs for operation and servicing of the inFlux will be provided by the Siteman Cancer Center and offset by user fees. An advisory committee consisting of senior leadership from the Siteman Cancer Center will oversee management and utilization of the inFlux. The Major Users, all established and funded scientists with significant cytometry expertise, will account for 100% of utilization in year one and a minimum of 75% in subsequent years. The remaining hours will be allocated to other investigators at Washington University ant St. Louis University, with priority given to members of the Siteman Cancer Center. This instrument will provide added value for many funded projects at Washington University that collectively accounted for over $328M in total awards from the NIH in 2002, placing it third among medical centers in the United States.